ArticleScientific reports2025
SLC25A19 is a key prognostic marker for hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Evaluation and Validation Reveal Mitochondrial Solute Carrier SLC25A3 as a Novel Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLC25A19 is a protein that mediates the transport of thiamine pyrophosphate (TPP) across cell membranes, but its significance in cancer remains largely unknown. To address this knowledge gap, we conducted a pan-cancer analysis to investigate the role of SLC25A19 in cancer. To investigate the role of SLC25A19 in cancer, we obtained RNA-seq, survival, and clinicopathological data from 33 cancers in the TCGA database. We performed expression and survival analyses of SLC25A19 across these cancers. Additionally, we explored the diagnostic and prognostic value of SLC25A19 specifically in hepatocellular carcinoma (HCC). To understand the potential role of SLC25A19 in the immune microenvironment of HCC, we also analyzed its expression in relation to immune checkpoint genes. Then we identified the drug most strongly correlated with SLC25A19 expression in HCC. Finally, PCR and Western-Blotting experiments were performed on HCC and its paracancer tissues to verify the expression of SLC25A19. Our analysis revealed that SLC25A19 is overexpressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis. We also found that high expression of SLC25A19 in HCC is associated with high expression of immune checkpoint genes, suggesting a potential role for SLC25A19 in immunotherapy. Furthermore, we identified drugs that are most strongly correlated with SLC25A19 expression in HCC, which could inform treatment decisions for HCC patients. PCR results showed that the expression of SLC25A19 in HCC was significantly up-regulated in 6 pairs of HCC and adjacent normal tissues. Our study can provide a reference for the diagnosis and treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.